Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3CNS 3Thoracic 2Other hematologic neoplasm 2Head & Neck 2Tumor-Agnostic 1Plasma cell 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 26Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 20Paclitaxel 12Standard of Care 10Carboplatin 10Blood Specimen Collection 10Bevacizumab 10atezolizumab 9Nivolumab 9Cisplatin 8Radiosurgery 7Pemetrexed 7Capecitabine 7Surveys and Questionnaires 6Gemcitabine 6Cyclophosphamide 6trastuzumab deruxtecan 5durvalumab 5X-Rays 5Taxes 5Radiotherapy 5Irinotecan 5Fluorouracil 5olaparib 4niraparib 4cabozantinib 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
omipalisib × Tumor-Agnostic × 90 days × Clear all
NCT02079740 2026-05-28

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡